Thiazolidinediones and Congestive Heart Failure
- 1 May 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Cardiology in Review
- Vol. 17 (3) , 132-135
Abstract
Thiazolidinediones are oral antihyperglycemic drugs that have gained significant popularity for use in the treatment of type 2 diabetes mellitus. Their insulin sensitizing effects lead to better glycemic control, in addition to improvements in several cardiovascular parameters independent of blood glucose levels. The pleiotropic effects of thiazolidinediones have led to several cardiovascular outcome studies, many of which have shown promising data, but some of which bring about significant concern. Additionally, the propensity to cause weight gain, fluid retention, peripheral edema, and increased risk of heart failure hospitalizations continue to pose significant challenges for clinicians using these agents in patients with congestive heart failure.Keywords
This publication has 46 references indexed in Scilit:
- Trends in Cardiovascular Complications of DiabetesJAMA, 2004
- The Incidence of Congestive Heart Failure in Type 2 DiabetesDiabetes Care, 2004
- The Evolving Diabetes Burden in the United StatesAnnals of Internal Medicine, 2004
- Metabolic and Additional Vascular Effects of ThiazolidinedionesDrugs, 2002
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 2000
- Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin actionDiabetologia, 2000
- Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patientsDiabetic Medicine, 2000
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionNew England Journal of Medicine, 1998
- Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells.Endocrinology, 1995
- Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with TroglitazoneNew England Journal of Medicine, 1994